Trastuzumab Recruiting Phase 1 Trials for Breast Cancer Treatment

IndicationsStatusPurposePhase
RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01969643A Safety Study of SGN-LIV1A in Breast Cancer Patients
NCT03716180DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC
NCT03135171Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab